Day One

Wednesday 17th April 2024

8:30 am Check-In & Light Breakfast

8:50 am Chair’s Opening Remarks

Successfully Navigate Commercial Bottlenecks to Streamline Innovation in Digital Pathology Approvals for Widespread Adoption

9:00 am Computational Pathology – The Next Revolution in Cancer Diagnostics for Drug Development

  • Mark Gustavson Senior Director & Global Head of Computational Pathology & Translational Science, AstraZeneca


  • Computational Pathology provides greater analytical precision and potentially greater clinical accuracy enabling identification of best patients populations for clinical response to oncology therapies
  • Quantitative Continuous Scoring (QCS) was developed to both quantify target expression in individual tumour cells and to quantify spatial heterogeneity of expression
  • We will discuss how we are leveraging Computational Pathology approaches in drug development and our vision for Computational Pathology in drug development

9:30 am Unleashing Machine Learning for Disease State Prediction to Forecast Treatment Strategies


  • How can machine learning develop prognosis prediction based on pathological data?
  • Could pathological data determine pre-diagnostic biomarkers?
  • What steps are needed for the validation of prognosis biomarker development?

10:00 am Morning Refreshments & Speed Networking


As the Translational Digital Pathology & AI Summit unites for the first time, this valuable

session will ensure that you can connect with your peers in the room to make new and

lasting connections. All attendees will have the opportunity to meet and network with their

academic and industry equals.

Standardizing Digital Pathology Protocols & Best Practices for Seamless Integration & Transformative Translational Benefits

11:00 am Panel Discussion: Overcoming the Lack of Standardization in Digital Pathology to Drive Advances in Quality of Research, Diagnosis & Clinical Benefits to Patients


  • Emphasizing the importance of a standardized approach in digital pathology as we embrace digital advancement
  • Unveiling the exciting potential of standardizing digital pathology to enhance diagnostic precision and streamline research methodologies
  • Navigating novel challenges with standardization when overcoming sensitivity hurdles that impede access to data

12:00 pm How AI-Powered Spatial Insights Are Being Integrated into Drug Development and Diagnostics


  • Examples of how the new wave of therapeutics such as antibody-drug conjugates (ADCs), multispecifics, and immunotherapy can benefit from AI-based spatial analysis of patient biopsies for extracting biomarker signatures that can predict response
  • How AI-based multimodal integration of different pathology and spatial data modalities (e.g., H&E, immunohistochemistry, multiplex immunofluorescence, spatial transcriptomics) can enhance the information derived from each tissue sample
  • How digital pathology standardization efforts and integration of multiplex immunofluorescence assays in clinical trial enrollment can drive the field of pathology-based diagnostics into the new digital biology era

12:30 pm Lunch Break & Networking

Harnessing AI & Spatial Biology to Enhance Biomarker Discovery & Disease Monitoring to Expand Treatment Options for Patients

1:30 pm Considering ML/AI from a Drug Development Pipeline Perspective

  • Lauri Diehl Executive Director - Research Pathology, Gilead Sciences


  • Role of machine learning/AI changes based on needs of each stage
  • Discovery research – building question specific ML toolkits
  • Translational studies – leveraging ML tools to describe populations
  • Clinical trials – ML tools and AI opportunities
  • What do you need to understand about ML/AI?
  • The importance of defining a scientific question endpoints

2:00 pm Analyzing Pathology Via AI Models to Augment Drug Development – An Oncologist’s Perspective

  • Yoojoo Lim Medical Director - Oncologist, Lunit Inc.


  • Quantitation of Tumor Infiltrating Lymphocytes from H&E slides holds predictive potential for IO therapy
  • Analysis of other tumor characteristics from H&E slides offer further predictive potential for novel IO combinations and therapies
  • Immunohistochemical (IHC) images can be quantitated to support target assessment for therapeutics

2:30 pm Afternoon Networking Break

Exploiting Machine Learning Across Drug Development Pipelines to Get Safer Drugs to Patients Faster

3:30 pm Roundtable Discussion: Establishing a Uniform Protocol in Digital Pathology Development for Effective Application in Translational & Clinical Studies


  • How can we streamline steps to establish a standardized imaging protocol to ensure consistent quality across digital pathology practices?
  • What steps are needed to improve cross departmental (or interlab) communication for more effective application of pathological insights?
  • In what ways are artificial intelligence and machine learning shaping the standardization of protocols in digital pathology? 
  • How can we validate solutions in a way that will ensure consistent performance of analyses based on digital pathology?

4:30 pm Lessons to be Learned from Academic Institutions for the Facilitated Adoption of Digital Pathology


  • Leveraging experiences of adoption of digital pathology in academic medical centers to facilitate patient care
  • Examining the impact of digital pathology to improve patient safety

5:00 pm Chair’s Closing Remarks & End of Day One